Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Antibiotics against CRE Chosen for Japan’s Revenue-Guarantee Pilot Project
The Ministry of Health, Labor and Welfare (MHLW) has nominated antimicrobials that work against Carbapenem-resistant Enterobacteriaceae (CRE) to be the products supported under its pilot project on a revenue-guarantee system in FY2023. The system is designed as a pull incentive…
To read the full story
Related Article
- Japan Panel Designates Two Ebola Therapies for Early Approval Pathway
April 1, 2026
- Japan Cabinet Approves National MCM Strategy to Boost Pandemic Response
March 25, 2026
- Japan Govt Council Finalizes Recommendations for National MCM Strategy
February 25, 2026
- Shionogi’s Cefiderocol Selected for Pilot-Based Revenue Assurance System
November 13, 2023
- Japan to Soon Start Taking Applications for Antibiotic Revenue Guarantee Program
September 6, 2023
- Japan Sees Delay in Pilot-Based Revenue Assurance System for Antibiotics, Criteria Still Up in Air
August 9, 2023
- 1.1 Billion Yen for Revenue Guarantee System for Antibiotics: FY2023 Budget
December 27, 2022
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…